XL177A is a potent and selective irreversible inhibitor of USP7 with an IC50 of 0.34 nM. Its anti-cancer activity is mediated through p53-dependent apoptosis, making it a valuable chemical probe for studying ubiquitination pathways in oncology research, both in vitro and in vivo.